Westfield Capital Trims Stake in GeneDx Holdings

Institutional investor reduces position in genomic testing company

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Westfield Capital Management Co. LP, an institutional investor, lowered its stake in GeneDx Holdings Corp. (NASDAQ:WGS) by 7.7% during the third quarter, according to a recent SEC filing. The firm now owns 544,094 shares of the company's stock, valued at around $58.6 million.

Why it matters

GeneDx is a leading provider of comprehensive genetic and genomic testing services, with a focus on rare and inherited disorders. The company's stock has seen significant volatility in recent months, and institutional investor activity can provide insights into market sentiment and the stock's performance.

The details

According to the filing, Westfield Capital Management sold 45,094 shares of GeneDx during the third quarter, reducing its total position to 544,094 shares. The firm now owns approximately 1.88% of the company's outstanding shares. GeneDx's stock has been trading in the range of $55.17 to $170.87 over the past 52 weeks, with the company reporting revenue of $120.99 million and earnings per share of $0.14 in its most recent quarter.

  • Westfield Capital Management reduced its stake in GeneDx during the third quarter of 2025.

The players

Westfield Capital Management Co. LP

An institutional investment management firm that owns a stake in GeneDx Holdings Corp.

GeneDx Holdings Corp.

A clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Westfield Capital Management's stake in GeneDx could signal broader market concerns about the company's performance or the genomic testing industry as a whole. However, GeneDx remains a significant player in the field, and its stock continues to be closely watched by investors and analysts.